

Financial Tear Sheet

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$9.34
Change (%)	▼ 0.04 (0.43%)
Volume	508,530
52 Week Low	\$8.69
Market Cap	\$296,354,922
Rolling EPS	-3.39
PE Ratio	N/A
Shares Outstanding	31,729,649
Data as of 10/19/18 4:00 p.m. ET	



Recent Paratek Pharmaceuticals News & Events

	Date	Title
10/04/18 - 4:01 p.m. Paratek Announces Acceptance of European Marketing Authorization Application for Oral and Intravenous Omadacycline	10/23/18 12:00 p.m. through 10/23/18 2:00 p.m. ET	2018 Paratek Investor Day
10/03/18 - 4:05 p.m. Paratek Pharmaceuticals, Inc. to Host Investor Day on October 23, 2018		
10/02/18 - 6:37 p.m. Paratek Announces FDA Approval of NUZYRA™ (Omadacycline)		

SEC Filings

Filing Date	Form
10/18/18	8-K
10/16/18	4
10/16/18	4
10/16/18	4

Management

Michael F. Bigham Chief Executive Officer
and Chairman of the
Board

Evan Loh, M.D. President, Chief
Operating Officer and
Chief Medical Officer

Douglas W. Pagán Chief Financial Officer

Adam Woodrow Chief Commercial
Officer

William Haskel General Counsel and
Corporate Secretary

Randy Brenner Senior Vice President
- Regulatory, Quality
and Technical
Operations

Regina Paglia Senior Vice President
- Human Resources

Evan Tzanis Chief Development
Officer

Jason Burdette	Vice President - Technical Operations
Jeanne Jew	Senior Vice President - Business Development
Raj Padmanabhan	Vice President - Information Technology
Susan Perkins, J.D.	Vice President - Intellectual Property
Christine R. Coyne, MBA	Vice President - Marketing
Sarah Higgins	Vice President - Controller
Paul McGovern, M.D.	Vice President - Clinical and Medical Affairs
Steve Sandor, MBA, J.D.	Vice President - Market Access and Trade
Judith N. Steenbergen, PhD	Vice President, Medical Strategy and Communications

Data provided by Nasdaq. Minimum 15 minutes delayed.